Caliper Life Sciences Presents LabChip(R) Platform to the U.S. Food and Drug Administration

HOPKINTON, Mass., Nov. 2 /PRNewswire-FirstCall/ -- Caliper Life Sciences, Inc. (Nasdaq: CALP - News), a leading provider of life sciences tools, presented at a training session for reviewers from the United States Food and Drug Administration (FDA) on the benefits of the LabChip GX platform for high throughput screening and characterization assays for biological drugs. "We were pleased to accept the FDA's invitation to present our LabChip platform to a large group of reviewers. We believe the LabChip platform will accelerate the adoption of quality-by-design approaches that ultimately will improve the safety profiles of new biologics and vaccines," said Kevin Hrusovsky, CEO of Caliper Life Sciences. "Additionally, our discussions with FDA officials indicate that Caliper's LabChip platform may have applications for downstream manufacturing release assays and potentially as an inline quality control technique."Caliper invited pioneers in this field from Pfizer (PFE), Amgen (AMGN), and Biogen Idec (BIIB) to describe their analytical approaches for biologics characterization. These leading scientists presented to a standing-room-only group of approximately 75 FDA personnel and described an industry-wide need for analytical techniques that provide high throughput, predictive assessments of biological product quality. This need is being addressed by Caliper's LabChip GX platform, which provides high resolution analytical data on a time scale that is approximately 70 times faster than conventional capillary electrophoresis.In...
Click here to read the whole Article (external link)

Caliper Life Sciences Expands LabChip(R) GX Product Capabilities, Broadens Application Focus, and Achieves Adoption Milestones

HOPKINTON, Mass., Nov. 2 /PRNewswire-FirstCall/ -- Caliper Life Sciences, Inc. (Nasdaq: CALP - News), a leading provider of life sciences tools, today announced the availability of two new products that expand the LabChip GX product line: a GLP/GMP-compliant version of the operating software for the LabChip GX instrument that is amenable to manufacturing QC environments and a new protein assay with higher, silver stain levels of sensitivity. The LabChip GX platform has been broadly adopted by biopharmaceutical companies and academic institutions for protein therapeutics, vaccines, and nucleic acid applications. "Our LabChip GX platform provides unique speed, throughput, cost, and data quality advantages for biologicals and has just begun to be adopted by vaccine producers. The LabChip GX is ideally suited for high throughput characterization of subunit and virus-like particle vaccines, which have emerging uses for the H1N1 influenza, or swine flu, and similar viruses, and the LabChip EZ Reader(®) platform is being used to identify small molecule antiviral drugs that inhibit viral proteases," said Kevin Hrusovsky, CEO of Caliper Life Sciences. "We also plan to launch a high throughput glycan profiling reagent kit for seven different sugar groups this quarter to address a growing assay requirement for characterization of biologicals and vaccines. These revolutionary capabilities have led to the rapid adoption of the LabChip GX platform. In the third quarter of 2009, we sold the most LabChip units of any quarter since the introduct...
Click here to read the whole Article (external link)

Caliper Life Sciences Reports Third Quarter 2009 Results

HOPKINTON, Mass., Nov. 9 /PRNewswire-FirstCall/ -- Caliper Life Sciences, Inc. (Nasdaq: CALP - News) today reported results for its third quarter ended September 30, 2009. GAAP revenues increased by 4% to $32.2 million, from non-GAAP revenues of $31.0 million in the same period of 2008, which represents GAAP revenue of $34.0 million in the third quarter of 2008 reduced by $3.0 million for the impact of divested product lines. The overall increase in revenues was led by strong performance of the Company's IVIS Imaging and LabChip product families. Foreign currency changes did not have a significant impact on total revenue in the quarter. The Company achieved positive operating net cash flows of $2.8 million in the quarter as a result of effective inventory management coupled with year-to-date improved bottom-line performance. Third Quarter 2009 ResultsSee "Use of Non-GAAP Financial Measures" below.Recent Business Highlights"With solid momentum with IVIS imaging and LabChip sales, we believe our strong performance will continue into the fourth quarter and 2010," commented Kevin Hrusovsky, Caliper's president and CEO. "We have delivered positive operating cash flows year-to-date and are targeting positive cash flows for full year 2009. Meeting this goal would exceed our previously stated expectations by a full year. This has been accomplished despite delays in the next EPA task order. With the initial Phase II task order now in hand, we are anticipating strong double-digit growth...
Click here to read the whole Article (external link)

Caliper Awarded New Task Order for EPA ToxCast Program

HOPKINTON, Mass., Nov. 9 /PRNewswire-FirstCall/ -- Caliper Life Sciences, Inc. (Nasdaq: CALP - News), a leading provider of tools and services for drug discovery and life sciences research, today announced that its Caliper Discovery Alliances and Services (CDAS) unit has been awarded a new funding commitment for $1.8 million under its contract with the Environmental Protection Agency (EPA) for the EPA's ToxCast screening program. This new task order increases the cumulative funding Caliper has been awarded under the ToxCast program to $5.6 million. "We are pleased to receive this new order from the EPA, which we believe further validates Caliper's capabilities and performance in the area of predictive toxicology screening assays. This new task order confirms Caliper's future role in the EPA's ToxCast program, and supports our belief that our funded activities will continue to expand as work starts on the new set of compounds in the coming year. We believe this task order will help fuel strong double-digit growth by our CDAS business in 2010 to complement our continuing strong imaging and microfluidic growth outlook," commented Kevin Hrusovsky, President and CEO of Caliper.Caliper has been working with EPA on its ToxCast program since 2007. The initial goal of the ToxCast program is to create a database of in vitro (laboratory) assay data on a broad set of compounds for which in vivo (animal) safety data already exists. The long term goal of ToxCast is to identify in vitro assays that can predict toxicity in humans and ani...
Click here to read the whole Article (external link)

Q3 2009 Caliper Life Sciences Earnings Release - 07:00 am ET

Earnings Announcements for Monday, November 9CompanySymbolTimeConferenceCall4Kids EntertainmentKDEBefore Market OpenAbatixABIX.PKAfter Market CloseAbraxas PetroleumAXASAfter Market CloseListenACADIA PHARMACEUTICALS INCACADAfter Market CloseADVANCED BATTERY TECHNOLOG INCABATAfter Market CloseAdvanced PhotonixAPIAfter Market CloseListenAdvanta CorporationADVNATime Not SuppliedAdvocatAVCAAfter Market CloseListenAlbany Molecular ResearchAMRIBefore Market OpenAlesco Financial Inc.AFNAfter Market CloseAlexza Pharmaceuticals Inc.ALXAAfter Market CloseListenAlliance One International, Inc.AOIAfter Market CloseAllianz SEAZSEY.PK01:30 am ETListenALLION HEALTHCARE INCALLITime Not SuppliedALPHATEC HOLDINGS INCATECTime Not SuppliedAmerican CareSource Holdings, Inc.ANCIAfter Market CloseA...
Click here to read the whole Article (external link)

Caliper Life 3Q loss narrows on lower costs

Copyright © 2009 Yahoo! All rights reserved. Privacy Policy - Terms of Service - Copyright Policy - Report Problems Quotes and other information supplied by independent providers identified on the Yahoo! Finance partner page. Quotes are updated automatically, but will be turned off after 25 minutes of inactivity. Quote data delayed 15 minutes for Nasdaq, NYSE and Amex. Real-Time continuous streaming quotes are available through our premium service. You may turn streaming quotes on or off. All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Yahoo! is not an investment adviser and does not provide, endorse or review any information or data contained herein....
Click here to read the whole Article (external link)

Caliper Life Sciences Earnings Call scheduled for 9:00 am ET today

Call DetailsCaliper Life Sciences Earnings Conference Call (Q3 2009)Mon, Nov 9, 2009, 9:00 am EasternAbout Caliper Life Sciences (NasdaqGM:CALP)Caliper Life Sciences, Inc. develops and sells products and services to pharmaceutical and biotechnology companies, and government and other not-for-profit research institutions worldwide. Its integrated systems consist of instruments, software and reagents, laboratory automation tools, and assay and discovery services. The company offers a portfolio of molecular imaging, microfluidics, automation and liquid handling technologies, and scientific applications to address various limitations in the drug discovery and development process. Its products include IVIS Imaging Systems and Living Image Software, an integrated optical molecular imaging solution; Light-Producing Cells and Microorganisms to analyze the spread and treatment of cancer and infectious diseases, as well as to study immunology; Light Producing Transgenic Animal models to analyze gene expression, protein activity, and disease progression; and luciferin, a chemical compound to produce bioluminescence, and VivoFluor fluorescent labeling kits for fluorescent imaging. The company’s products also comprise LabChip 3000 Drug Discovery System, which produces data that minimizes false positives and false negatives, and detects weak inhibitors; LabChip EZ Reader, EZ Reader II, and ProfilerPro Kits; Caliper Sciclone that incorporates automated microplate carriers; Zephyr, a liquid handling instrument; staccato automated workstations for drug discovery, genomics, proteomics, and drug development laboratories; Twister I and II, which automate the movement of microplates; MultiDose G3, an automated dissolution testing system; and active pharmaceutical ingredient workstation. In addition, it offers contract research and transgenic animal services, drug discov...
Click here to read the whole Article (external link)

CALIPER LIFE SCIENCES INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and

Show all filings for CALIPER LIFE SCIENCES INC | Request a Trial to NEW EDGAR Online Pro Form 8-K for CALIPER LIFE SCIENCES INC 9-Nov-2009Results of Operations and Financial Condition, Financial Statements and Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information...
Click here to read the whole Article (external link)

CALIPER LIFE SCIENCES INC Financials

Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback Quotes delayed, except where indicated otherwise.Delay times are 15 mins for NASDAQ, 20 mins for NYSE and Amex. See also delay times for other exchanges.Fundamental company data provided by Capital IQ. Quotes and other information supplied by independent providers identified on the Yahoo! Finance partner page. Quotes are updated automatically, but will be turned off after 25 minutes of inactivity. Quotes are delayed at least 15 minutes. Real-...
Click here to read the whole Article (external link)